NasdaqCM - Nasdaq Real Time Price USD

Senti Biosciences, Inc. (SNTI)

4.4300

+0.4300

+(10.75%)

At close: 4:00:00 PM EDT

4.4400

+0.01

+(0.23%)

After hours: 5:01:39 PM EDT

Senti Bio Participates in a Virtual Investor KOL Connect Segment

Moderated discussion with Stephen Strickland, MD, MSCI, internationally respected leukemia researcher, Director of Leukemia Research for Sarah Cannon Research Institute and Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio KOL Connect segment now available here SOUTH SAN FRANCISCO, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation

GlobeNewswire 2 days ago

SNTI
+10.75%
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment

Live moderated webcast with members of the Senti Bio management team on Wednesday, April 23rd at 4:00 PM ETSOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that will participate in the Virtual Investor Closing Bell Series on Wednesday, April 23, 2025 at 4:00 PM E

GlobeNewswire 7 days ago

SNTI
+10.75%
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from “bench to bedside” and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotec

GlobeNewswire 13 days ago

SNTI
+10.75%
Senti Bio Joins Webull Corporate Connect Service Platform

Company advancing off-the-shelf CAR-NK cell therapy programs for oncology indications with lead candidate, SENTI-202, in clinical development for the treatment of acute myeloid leukemia (AML) Connect with the Company on Webull here SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform

GlobeNewswire 16 days ago

SNTI
+10.75%
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

New data to be presented from Company’s lead product candidate SENTI-202 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) development programSOUTH SAN FRANCISCO, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that three abstracts have been selected for an o

GlobeNewswire 20 days ago

SNTI
+10.75%
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights

– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened balance sheet with gross proceeds of approximately $47.6 million from private investment in public equity (PIPE) financing – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company

GlobeNewswire last month

SNTI
+10.75%
Senti Bio Appoints Feng Hsiung to Board of Directors

– Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) –SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio,” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Feng Hsiung, an executive with extensive business, finance and investment experience, to the Senti Bio Board o

GlobeNewswire last month

SNTI
+10.75%
Senti Bio Strengthens Leadership Team with Strategic Hires

– Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced an expansion of its senior leadership team

GlobeNewswire last month

SNTI
+10.75%
US Penny Stocks To Watch In January 2025

As the S&P 500 reaches another record high, investors are keeping a close eye on market movements, driven by strong corporate earnings and recent policy announcements. While traditionally associated with higher risk, penny stocks—representing smaller or newer companies—can still present valuable opportunities for those willing to explore beyond the major indices. By focusing on firms with solid financial foundations and potential for growth, investors can uncover promising prospects among...

Simply Wall St. 2 months ago

WYY

VFF

SNTI
+10.75%
Senti Bio Announces Additional $11.5 Million of Financing

– Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced in June 2024 – – Cash runway guidance extended into 2026 – SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has secured

GlobeNewswire 3 months ago

SNTI
+10.75%
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”) – SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the first patient has been dosed in the p

GlobeNewswire 4 months ago

SNTI
+10.75%
Senti Bio price target raised to $12 from $10 at Chardan

Chardan analyst Geulah Livshits raised the firm’s price target on Senti Bio (SNTI) to $12 from $10 and keeps a Buy rating on the shares after the company reported data and hosted a call to discuss initial results from the Phase 1 trial of its donor-derived logic-gated CARNK SENTI-202 in relapsed/refractory hematologic malignancies. Having “digested the data in a bit more detail,” the firm increased its view of the probability of success for SENTI-202 to 35% from 25%, the analyst tells investors.

TipRanks 4 months ago

SNTI
+10.75%
Senti Biosciences Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on November 26, 2024, the Compensation Committee of Senti Bio’s Board of Directors granted to three new employees stock options to purchase an aggregate of 49,778 shares of the Company’s common stock with a per share exercise p

GlobeNewswire 4 months ago

SNTI
+10.75%
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study

Senti Bio posts upbeat initial data from a phase I study on SENTI-202 for the treatment of relapsed/refractory hematologic malignancies. Stock soars.

Zacks 4 months ago

SNTI
+10.75%
Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202

The company states: “Senti Bio (SNTI)science reported positive initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural kille investigational cell therapy, for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia. SENTI-202 is designed to selectively target and eliminate CD33 and/or FLT3- expressing hematologic malignancies, including AML, while sparing health

TipRanks 4 months ago

SNTI
+10.75%
Sector Update: Health Care Stocks Slipping Late Afternoon

Health care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health

PREMIUM
MT Newswires 4 months ago

PTCT

SNTI
+10.75%
NVS
Why Is Senti Biosciences Stock Surging Over 400% On Monday?

Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro. The company reported initial clinical data from a Phase 1 trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for relapsed/refractory hematologic malignancies including acute myeloid leukemia. SENTI-202

Benzinga 4 months ago

SNTI
+10.75%
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 16,713 shares of Series A Convertible Preferred Stock (the “Preferred Stock”) through a private i

GlobeNewswire 4 months ago

SNTI
+10.75%
$Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML$

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML

– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile – – Dose escalation is continuing with additional response and durability data expected in 2025 – – Conference call scheduled on December 3 at 7:30am ET – SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generat

GlobeNewswire 4 months ago

SNTI
+10.75%
Senti Bio Appoints Fran Schulz to Board of Directors

Biotechnology industry executive with a proven track record of advising management teams on corporate and financial strategy for more than 30 yearsSOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Fran Schulz, a highly experienced biotechnolog

GlobeNewswire 4 months ago

EDAP

SNTI
+10.75%

Performance Overview

Return	SNTI	S&P 500 (^GSPC)
YTD	+26.21%	-8.60%
1-Year	+47.67%	+6.02%
3-Year	-95.51%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Senti Biosciences, Inc. (SNTI)

Senti Bio Participates in a Virtual Investor KOL Connect Segment

Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment

Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

Senti Bio Joins Webull Corporate Connect Service Platform

Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights

Senti Bio Appoints Feng Hsiung to Board of Directors

Senti Bio Strengthens Leadership Team with Strategic Hires

US Penny Stocks To Watch In January 2025

Senti Bio Announces Additional $11.5 Million of Financing

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

Senti Bio price target raised to $12 from $10 at Chardan

Senti Biosciences Announces New Employment Inducement Grants

SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study

Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202

Sector Update: Health Care Stocks Slipping Late Afternoon

Why Is Senti Biosciences Stock Surging Over 400% On Monday?

Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML

Senti Bio Appoints Fran Schulz to Board of Directors

Performance Overview